On August 5, DaVita HealthCare Partners fell 6.14% in after-hours trading, trading at approximately $213.99/share, with turnover of $37.81 million. The decline came despite a strong Q2 earnings beat, as the company maintained its full-year guidance unchanged, disappointing investors who had expected a raise.

DaVita reported Q2 adjusted EPS of $4.02, beating the consensus estimate of $3.88 by 3.61% and representing a 36.27% year-over-year increase from $2.95. Revenue came in at $3.554 billion, surpassing the $3.496 billion estimate. However, the company reiterated its full-year adjusted EPS guidance of $14.10-$15.20, in line with the FactSet estimate of $14.88 but unchanged from the range issued after Q1. Given that both Q1 and Q2 significantly exceeded expectations, the market had widely anticipated a guidance raise. The decision to hold guidance steady was interpreted as an implicit signal of decelerating earnings momentum in the second half, triggering selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)